Fetal and neonatal alloimmune thromboctyopenia due to maternal human platelet antigen (HPA)-1a antibodies affects primigravidas. Immunization must occur early in pregnancy before fetal platelets enter maternal blood via fetomaternal hemorrhage. The HPA-1a antigen is located on platelet glycoprotein (GP)IIIa (CD61, beta3 integrin), which is also present on the placental syncytiotrophoblast (ST) and in direct contact with maternal blood. Since ST debris is shed into maternal blood during pregnancy, this material might be immunogenic in vivo. For experimental purposes, we prepared and characterized ST microparticles (STMPs) in vitro from term placentas. Phenotype analysis by flow cytometry and Western blotting showed that STMP expressed more placental alkaline phosphatase (PLAP) than GPIIIa. Quantitative real-time PCR demonstrated expression of human placental lactogen (HPL), human chorionic gonadotrophin (HCG), and GPIIIa by STMP, in the order HPL > HCG > GPIIIa. PLAP, HPL, and HCG are trophoblast-specific proteins. These STMPs may be a useful model for studying the natural ST debris in plasma of pregnant women.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1196/annals.1448.017 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Preeclampsia and eclampsia: Enhanced detection and treatment for morbidity reduction.
Best Pract Res Clin Anaesthesiol
September 2024
Division of Maternal-Fetal Medicine, Brigham and Women's Hospital, Harvard Medical School, 75 Francis St, L1, Boston, MA, 02115, USA. Electronic address:
Preeclampsia is a life-threatening complication that develops in 2-8% of pregnancies. It is characterized by elevated blood pressure after 20 weeks of gestation and may progress to multiorgan dysfunction, leading to severe maternal and fetal morbidity and mortality. The only definitive treatment is delivery, and efforts are focused on early risk prediction, surveillance, and severity mitigation.
View Article and Find Full Text PDFNavigating coagulopathy in obstetric hemorrhage: The role of point-of-care testing.
Best Pract Res Clin Anaesthesiol
September 2024
Department of Anaesthesia and Perioperative Medicine, Cardiff and Vale University Hospital, Cardiff, UK.
Postpartum hemorrhage (PPH) remains the leading cause of maternal mortality and morbidity worldwide. Recent advances in understanding the hemostatic changes of pregnancy and PPH have led to the development of obstetric-specific approaches to resuscitation. This article aims to examine.
View Article and Find Full Text PDFPostpartum hemorrhage assessment and targeted treatment.
Best Pract Res Clin Anaesthesiol
September 2024
Department of Anesthesiology, Perioperative, and Pain Medicine, Brigham and Women's Hospital, Harvard Medical School, 75 Francis St, Boston, MA, 02115, USA. Electronic address:
Postpartum hemorrhage (PPH) is the leading cause of maternal mortality worldwide, and mitigating it is a global health priority. In this review, we discuss the measurement, assessment, and treatment of PPH. We review different methods of quantifying blood loss, including gravimetry, calibrated drapes and canisters, and colorimetric techniques.
View Article and Find Full Text PDFObesity Prevalence and Its Impact on Maternal and Neonatal Outcomes in Pregnant Women: A Systematic Review.
Cureus
December 2024
Obstetrics and Gynecology, Maternity and Children Hospital, Hail, SAU.
Globally, obesity prevalence has progressively increased and is now at epidemic levels; this trend is mirrored in women of childbearing age. There is a high level of evidence that maternal obesity is associated with a range of adverse pregnancy complications and neonatal outcomes, such as hypertensive disorders of pregnancy, gestational diabetes mellitus (GDM), large for gestational age (LGA) fetuses, premature birth, stillbirth, cesarean section, and postpartum hemorrhage, among certain others. This systematic review aimed to comprehensively evaluate the relationship between maternal obesity and health outcomes for both mothers and infants.
View Article and Find Full Text PDFLH level on trigger day, number of follicles ≥16 mm but <18 mm, and number of retrieved oocytes are independent risk factors for polyspermy in gonadotropin-releasing hormone antagonist protocol.
Front Endocrinol (Lausanne)
January 2025
Department of Reproductive Health and Infertility, Zigong Maternal and Child Health Hospital, Zigong, Sichuan, China.
Introduction: The polyspermy rate is a quality control indicator in the embryology laboratory, and factors affecting polyspermy are of great interest. The gonadotropin-releasing hormone (GnRH) antagonist protocol is currently the mainstream protocol in most reproductive centers. This study explored the factors influencing polyspermy in fertilization (IVF) using the GnRH antagonist protocol and considered corresponding improvement measures.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!